This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Reply to Letter to the Editor “Sexual Dysfunction on Fluvoxamine Therapy”

Anne N. Nafziger, Joseph S. Bertino, Jr., Angelica I. Goss-Bley, and Angela D. M. Kashuba

Published: June 30, 2000

Article Abstract

Letter to the Editor

Sir: We thank Dr. Laird for his thoughtful comments about our article. This study was an open-label clinical trial with fluvoxamine used as a hepatic enzyme inhibitor, as clearly stated in our Method section. The problems associated with open-label studies are well known, as are the benefits and problems associated with double- and triple-blind studies.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 61

Quick Links: Depression (MDD) , Sexual Dysfunction


Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...